{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/8810"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/8810","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"Dermatan Sulfate: A New Concept in Antithrombotic Therapy","abstract":"<p>This study was undertaken to explore the hypothesis<br />that dermatan sulfate, which catalyses thrombin inhibition by<br />heparin cofactor II, prevents thrombosis more effectively than<br />heparin, which catalyses thrombin inhibition by antithrombin<br />III. The rationale for this hypothesis is based upon three<br />general observations. First, higher doses of heparin are<br />required for the treatment of thrombus growth than are<br />required for the prevention of thrombus formation. Second,<br />thrombin bound to fibrin or to vessel wall components in vitro<br />is resistant to inhibition by heparin/antithrombin III.<br />Third, preliminary evidence indicates that the catalysis of<br />thrombin inhibition by antithrombin III-independent inhibitors<br />may be more effective than heparin/antithrombin III. The<br />results of this present study support the above hypothesis and<br />demonstrated that dermatan sulfate, a glycosaminoglycan which<br />catalyses thrombin inhibition by heparin cofactor II,<br />inhibited i) thrombus formation, ii) thrombus growth, and iii)<br />acted synergistically with tPA to enhance thrombolysis, more<br />effectively than heparin. These effects were achieved with minimal detrimental side-effects. These results indicate that<br />dermatan sulfate is an effective antithrombotic agent and<br />support the conclusion that the catalysis of thrombin<br />inhibition by dermatan sulfate/heparin cofactor II provides<br />a more effective pathway for preventing thrombus formation and<br />thrombus growth than the catalysis of thrombin inhibition by<br />heparin/antithrombin III.</p>","abstract_html":"&lt;p&gt;This study was undertaken to explore the hypothesis&lt;br /&gt;that dermatan sulfate, which catalyses thrombin inhibition by&lt;br /&gt;heparin cofactor II, prevents thrombosis more effectively than&lt;br /&gt;heparin, which catalyses thrombin inhibition by antithrombin&lt;br /&gt;III. The rationale for this hypothesis is based upon three&lt;br /&gt;general observations. First, higher doses of heparin are&lt;br /&gt;required for the treatment of thrombus growth than are&lt;br /&gt;required for the prevention of thrombus formation. Second,&lt;br /&gt;thrombin bound to fibrin or to vessel wall components in vitro&lt;br /&gt;is resistant to inhibition by heparin/antithrombin III.&lt;br /&gt;Third, preliminary evidence indicates that the catalysis of&lt;br /&gt;thrombin inhibition by antithrombin III-independent inhibitors&lt;br /&gt;may be more effective than heparin/antithrombin III. The&lt;br /&gt;results of this present study support the above hypothesis and&lt;br /&gt;demonstrated that dermatan sulfate, a glycosaminoglycan which&lt;br /&gt;catalyses thrombin inhibition by heparin cofactor II,&lt;br /&gt;inhibited i) thrombus formation, ii) thrombus growth, and iii)&lt;br /&gt;acted synergistically with tPA to enhance thrombolysis, more&lt;br /&gt;effectively than heparin. These effects were achieved with minimal detrimental side-effects. These results indicate that&lt;br /&gt;dermatan sulfate is an effective antithrombotic agent and&lt;br /&gt;support the conclusion that the catalysis of thrombin&lt;br /&gt;inhibition by dermatan sulfate/heparin cofactor II provides&lt;br /&gt;a more effective pathway for preventing thrombus formation and&lt;br /&gt;thrombus growth than the catalysis of thrombin inhibition by&lt;br /&gt;heparin/antithrombin III.&lt;/p&gt;","abstract_has_math":false,"creators":["Ryn-McKenna, Van Joanne"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Physiology and Pharmacology","school":null,"contributors":[],"advisors":["Buchanan, M.R."],"committee_chairs":[],"committee_members":[],"year":1991,"date_issued":"1991-04","date_published":"1991-04","updated_at":"2026-11-18T19:33:50Z","subjects":["Pharmacology"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/15040"],"render_values":[{"text":"https://doi.org/10.71548/15040","href":"https://doi.org/10.71548/15040","code":true}]},{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/3984","5001","1884582"],"render_values":[{"text":"opendissertations/3984","href":null,"code":true},{"text":"5001","href":null,"code":true},{"text":"1884582","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/11375/8810","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"http://hdl.handle.net/11375/8810","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F8810","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Buchanan, M.R."]},{"key":"dc:contributor.department","label":"Department","values":["Physiology and Pharmacology"]},{"key":"dc:creator","label":"Author","values":["Ryn-McKenna, Van Joanne"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-06-18T16:44:04Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2014-06-18T16:44:04Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2011-03-18"]},{"key":"dc:date.issued","label":"Date","values":["1991-04"]},{"key":"dc:type","label":"Dc Type","values":["thesis"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Pharmacology"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["opendissertations/3984","5001","1884582"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/11375/8810","https://doi.org/10.71548/15040"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["<p>This study was undertaken to explore the hypothesis<br />that dermatan sulfate, which catalyses thrombin inhibition by<br />heparin cofactor II, prevents thrombosis more effectively than<br />heparin, which catalyses thrombin inhibition by antithrombin<br />III. The rationale for this hypothesis is based upon three<br />general observations. First, higher doses of heparin are<br />required for the treatment of thrombus growth than are<br />required for the prevention of thrombus formation. Second,<br />thrombin bound to fibrin or to vessel wall components in vitro<br />is resistant to inhibition by heparin/antithrombin III.<br />Third, preliminary evidence indicates that the catalysis of<br />thrombin inhibition by antithrombin III-independent inhibitors<br />may be more effective than heparin/antithrombin III. The<br />results of this present study support the above hypothesis and<br />demonstrated that dermatan sulfate, a glycosaminoglycan which<br />catalyses thrombin inhibition by heparin cofactor II,<br />inhibited i) thrombus formation, ii) thrombus growth, and iii)<br />acted synergistically with tPA to enhance thrombolysis, more<br />effectively than heparin. These effects were achieved with minimal detrimental side-effects. These results indicate that<br />dermatan sulfate is an effective antithrombotic agent and<br />support the conclusion that the catalysis of thrombin<br />inhibition by dermatan sulfate/heparin cofactor II provides<br />a more effective pathway for preventing thrombus formation and<br />thrombus growth than the catalysis of thrombin inhibition by<br />heparin/antithrombin III.</p>"]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Doctor of Philosophy (PhD)"]},{"key":"dc:title","label":"Title","values":["Dermatan Sulfate: A New Concept in Antithrombotic Therapy"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Buchanan, M.R."],"dc:contributor.department":["Physiology and Pharmacology"],"dc:creator":["Ryn-McKenna, Van Joanne"],"dc:date.accessioned":["2014-06-18T16:44:04Z"],"dc:date.available":["2014-06-18T16:44:04Z"],"dc:date.created":["2011-03-18"],"dc:date.issued":["1991-04"],"dc:description.abstract":["<p>This study was undertaken to explore the hypothesis<br />that dermatan sulfate, which catalyses thrombin inhibition by<br />heparin cofactor II, prevents thrombosis more effectively than<br />heparin, which catalyses thrombin inhibition by antithrombin<br />III. The rationale for this hypothesis is based upon three<br />general observations. First, higher doses of heparin are<br />required for the treatment of thrombus growth than are<br />required for the prevention of thrombus formation. Second,<br />thrombin bound to fibrin or to vessel wall components in vitro<br />is resistant to inhibition by heparin/antithrombin III.<br />Third, preliminary evidence indicates that the catalysis of<br />thrombin inhibition by antithrombin III-independent inhibitors<br />may be more effective than heparin/antithrombin III. The<br />results of this present study support the above hypothesis and<br />demonstrated that dermatan sulfate, a glycosaminoglycan which<br />catalyses thrombin inhibition by heparin cofactor II,<br />inhibited i) thrombus formation, ii) thrombus growth, and iii)<br />acted synergistically with tPA to enhance thrombolysis, more<br />effectively than heparin. These effects were achieved with minimal detrimental side-effects. These results indicate that<br />dermatan sulfate is an effective antithrombotic agent and<br />support the conclusion that the catalysis of thrombin<br />inhibition by dermatan sulfate/heparin cofactor II provides<br />a more effective pathway for preventing thrombus formation and<br />thrombus growth than the catalysis of thrombin inhibition by<br />heparin/antithrombin III.</p>"],"dc:description.degree":["Doctor of Philosophy (PhD)"],"dc:identifier.other":["opendissertations/3984","5001","1884582"],"dc:identifier.uri":["http://hdl.handle.net/11375/8810","https://doi.org/10.71548/15040"],"dc:subject":["Pharmacology"],"dc:title":["Dermatan Sulfate: A New Concept in Antithrombotic Therapy"],"dc:type":["thesis"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:33:50Z"}